Matches in SemOpenAlex for { <https://semopenalex.org/work/W2317100287> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W2317100287 endingPage "A7" @default.
- W2317100287 startingPage "A7.1" @default.
- W2317100287 abstract "The toxic effects of anthracycline antineoplastic drugs to cardiomyocytes is a a serious drawback of their high antineoplastic efficiency. Dexrazoxane remains the only clinically approved protective substance against the cardiotoxicitity of anthracycline antineoplastic drugs. Although the mechanisms of the cardioprotection are elusive so far, widely accepted hypothesis represents dexrazoxane as a pro-drug yielding an EDTA-like metabolite ADR-925. By chelating iron, ADR-925 could prevent oxidative damage induced by anthracyclines. However, the relationship of dexrazoxane hydrolysis and its cardioprotective activity is only poorly characterised. We found that the rate of dexrazoxane decay (100 µM) to ADR-925 in the culture medium does not change in the presence of the cardiomyocytes. We also observed that ADR-925 passes through the plasma membrane into the cells, although more slowly than dexrazoxane. In cells ADR-925 chelates free intracellular iron. Also ADR-925 is able to displace iron from its complex with anthracyclines in solution. Interestingly, both dexrazoxane and ADR-925 were found to interact with topoisomerase II in cells, although in a different manner. The plasma and tissue concentrations of dexrazoxane and ADR-925 were measured also using validated analytic methods in plasma, myocardium, soleus muscle, liver and urine samples after a one dose of dexrazoxane and ADR-925 to rabbits (60 mg/kg, i.p.) and fundamental pharmacokinetic parameters were calculated. We documented that ADR-925 crosses the plasma membrane and also interacts with the topoiosomerase II beta in cardiomyocytes. These findings together with the in vivo data provide a valuable insight into the pharmacokinetic/pharmacodnamic relationship of the dexrazoxane cardioprotection of anthracycline cardiotoxicity." @default.
- W2317100287 created "2016-06-24" @default.
- W2317100287 creator A5030741622 @default.
- W2317100287 creator A5033625369 @default.
- W2317100287 creator A5034860123 @default.
- W2317100287 creator A5045284531 @default.
- W2317100287 creator A5047132165 @default.
- W2317100287 creator A5051756183 @default.
- W2317100287 creator A5053769968 @default.
- W2317100287 creator A5056286052 @default.
- W2317100287 creator A5072001080 @default.
- W2317100287 date "2014-11-21" @default.
- W2317100287 modified "2023-10-11" @default.
- W2317100287 title "ANTHRACYCLINE CARDIOTOXICITY: THE PHARMACOKINETICS AND PHARMACODYNAMICS OF DEXRAZOXANE AND ITS OPEN RING METABOLITE" @default.
- W2317100287 doi "https://doi.org/10.1136/heartjnl-2014-306916.20" @default.
- W2317100287 hasPublicationYear "2014" @default.
- W2317100287 type Work @default.
- W2317100287 sameAs 2317100287 @default.
- W2317100287 citedByCount "0" @default.
- W2317100287 crossrefType "journal-article" @default.
- W2317100287 hasAuthorship W2317100287A5030741622 @default.
- W2317100287 hasAuthorship W2317100287A5033625369 @default.
- W2317100287 hasAuthorship W2317100287A5034860123 @default.
- W2317100287 hasAuthorship W2317100287A5045284531 @default.
- W2317100287 hasAuthorship W2317100287A5047132165 @default.
- W2317100287 hasAuthorship W2317100287A5051756183 @default.
- W2317100287 hasAuthorship W2317100287A5053769968 @default.
- W2317100287 hasAuthorship W2317100287A5056286052 @default.
- W2317100287 hasAuthorship W2317100287A5072001080 @default.
- W2317100287 hasConcept C112705442 @default.
- W2317100287 hasConcept C121608353 @default.
- W2317100287 hasConcept C126322002 @default.
- W2317100287 hasConcept C2776694085 @default.
- W2317100287 hasConcept C2776802502 @default.
- W2317100287 hasConcept C2777477808 @default.
- W2317100287 hasConcept C2778233292 @default.
- W2317100287 hasConcept C2779720357 @default.
- W2317100287 hasConcept C2781303535 @default.
- W2317100287 hasConcept C530470458 @default.
- W2317100287 hasConcept C71924100 @default.
- W2317100287 hasConcept C98274493 @default.
- W2317100287 hasConceptScore W2317100287C112705442 @default.
- W2317100287 hasConceptScore W2317100287C121608353 @default.
- W2317100287 hasConceptScore W2317100287C126322002 @default.
- W2317100287 hasConceptScore W2317100287C2776694085 @default.
- W2317100287 hasConceptScore W2317100287C2776802502 @default.
- W2317100287 hasConceptScore W2317100287C2777477808 @default.
- W2317100287 hasConceptScore W2317100287C2778233292 @default.
- W2317100287 hasConceptScore W2317100287C2779720357 @default.
- W2317100287 hasConceptScore W2317100287C2781303535 @default.
- W2317100287 hasConceptScore W2317100287C530470458 @default.
- W2317100287 hasConceptScore W2317100287C71924100 @default.
- W2317100287 hasConceptScore W2317100287C98274493 @default.
- W2317100287 hasIssue "Suppl 4" @default.
- W2317100287 hasLocation W23171002871 @default.
- W2317100287 hasOpenAccess W2317100287 @default.
- W2317100287 hasPrimaryLocation W23171002871 @default.
- W2317100287 hasRelatedWork W107711178 @default.
- W2317100287 hasRelatedWork W1979110296 @default.
- W2317100287 hasRelatedWork W1994519849 @default.
- W2317100287 hasRelatedWork W1999312626 @default.
- W2317100287 hasRelatedWork W2056254035 @default.
- W2317100287 hasRelatedWork W2305100815 @default.
- W2317100287 hasRelatedWork W2572049769 @default.
- W2317100287 hasRelatedWork W2998131233 @default.
- W2317100287 hasRelatedWork W3200938066 @default.
- W2317100287 hasRelatedWork W4237090850 @default.
- W2317100287 hasVolume "100" @default.
- W2317100287 isParatext "false" @default.
- W2317100287 isRetracted "false" @default.
- W2317100287 magId "2317100287" @default.
- W2317100287 workType "article" @default.